NYSE:ZYME - Zymeworks Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.95 +0.25 (+1.41 %)
(As of 05/22/2018 10:07 AM ET)
Previous Close$17.80
Today's Range$17.80 - $17.95
52-Week Range$6.25 - $18.00
Volume200 shs
Average Volume77,035 shs
Market Capitalization$433.15 million
P/E Ratio-31.05
Dividend YieldN/A
BetaN/A

About Zymeworks (NYSE:ZYME)

Zymeworks logoZymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Debt-to-Equity RatioN/A
Current Ratio4.09
Quick Ratio4.09

Price-To-Earnings

Trailing P/E Ratio-31.05
Forward P/E Ratio-6.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$51.76 million
Price / Sales8.83
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book3.91

Profitability

EPS (Most Recent Fiscal Year)($0.57)
Net Income$-10,400,000.00
Net Margins-30.41%
Return on Equity-16.07%
Return on Assets-13.65%

Miscellaneous

Employees147
Outstanding Shares25,460,000

Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks (NYSE:ZYME) issued its quarterly earnings data on Tuesday, May, 1st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.68) by $0.15. The business had revenue of $0.04 million for the quarter. Zymeworks had a negative net margin of 30.41% and a negative return on equity of 16.07%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

7 equities research analysts have issued 12 month price objectives for Zymeworks' stock. Their predictions range from $15.00 to $25.00. On average, they expect Zymeworks' share price to reach $20.1667 in the next twelve months. View Analyst Ratings for Zymeworks.

Who are some of Zymeworks' key competitors?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 46)
  • Mr. Neil Klompas C.A., C.P.A., CPA, CA, Chief Financial Officer (Age 46)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 55)
  • Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)
  • Mr. David Tucker, Chief Operating Officer

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Has Zymeworks been receiving favorable news coverage?

Headlines about ZYME stock have been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zymeworks earned a coverage optimism score of 0.14 on Accern's scale. They also gave headlines about the company an impact score of 47.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include PenderFund Capital Management Ltd. (1.28%) and Stanley Laman Group Ltd. (0.14%). View Institutional Ownership Trends for Zymeworks.

Which major investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including PenderFund Capital Management Ltd. and Stanley Laman Group Ltd.. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $17.95.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $433.15 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (ZYME)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zymeworks (NYSE:ZYME) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Zymeworks in the last 12 months. Their average twelve-month price target is $20.1667, suggesting that the stock has a possible upside of 12.35%. The high price target for ZYME is $25.00 and the low price target for ZYME is $15.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.672.602.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.1667$16.40$16.00$16.00
Price Target Upside: 12.35% upside38.28% upside100.50% upside100.50% upside

Zymeworks (NYSE:ZYME) Consensus Price Target History

Price Target History for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE:ZYME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Raymond JamesBoost Price TargetOutperform$18.00 ➝ $22.00LowView Rating Details
5/16/2018Canaccord GenuityBoost Price TargetBuy$18.00 ➝ $21.00MediumView Rating Details
5/14/2018Ladenburg ThalmannInitiated CoverageBuy$25.00LowView Rating Details
5/11/2018BarclaysUpgradeUnderweight ➝ Equal Weight$8.00 ➝ $15.00HighView Rating Details
9/30/2017CormarkReiterated RatingBuyMediumView Rating Details
5/23/2017CitigroupInitiated CoverageBuy ➝ Buy$18.00LowView Rating Details
5/23/2017Wells FargoInitiated CoverageOutperform ➝ Outperform$20.00LowView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Zymeworks (NYSE:ZYME) Earnings History and Estimates Chart

Earnings by Quarter for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE:ZYME) Earnings Estimates

2018 EPS Consensus Estimate: ($2.94)
2019 EPS Consensus Estimate: ($3.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.67)($0.67)($0.67)
Q2 20181($0.69)($0.69)($0.69)
Q3 20181($0.79)($0.79)($0.79)
Q4 20181($0.79)($0.79)($0.79)
Q1 20191($0.82)($0.82)($0.82)
Q2 20191($0.75)($0.75)($0.75)
Q3 20191($0.75)($0.75)($0.75)
Q4 20191($0.75)($0.75)($0.75)

Zymeworks (NYSE ZYME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/1/2018Q1 2018($0.68)($0.83)$0.04 millionViewN/AView Earnings Details
3/14/2018Q4 2017$1.28$50.07 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.74)($0.65)$0.12 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.63)$1.34 millionViewN/AView Earnings Details
5/15/2017Q1($1.13)$0.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zymeworks (NYSE:ZYME) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zymeworks (NYSE ZYME) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 8.09%
Insider Trading History for Zymeworks (NYSE:ZYME)
Institutional Ownership by Quarter for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE ZYME) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Zymeworks (NYSE ZYME) News Headlines

Source:
DateHeadline
Raymond James Increases Zymeworks (ZYME) Price Target to $22.00Raymond James Increases Zymeworks (ZYME) Price Target to $22.00
www.americanbankingnews.com - May 18 at 4:07 PM
Zymeworks (ZYME) Buy Rating Reiterated at Canaccord GenuityZymeworks' (ZYME) Buy Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - May 16 at 2:28 PM
Zacks: Brokerages Anticipate Zymeworks (ZYME) Will Post Earnings of -$0.69 Per ShareZacks: Brokerages Anticipate Zymeworks (ZYME) Will Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - May 15 at 5:14 PM
Zymeworks (ZYME), Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific AntibodiesZymeworks (ZYME), Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
www.streetinsider.com - May 15 at 9:38 AM
BRIEF-Zymeworks And Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused On Bispecific AntibodiesBRIEF-Zymeworks And Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused On Bispecific Antibodies
www.reuters.com - May 15 at 9:38 AM
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific AntibodiesZymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
finance.yahoo.com - May 15 at 9:38 AM
Zymeworks (ZYME) Given Average Recommendation of "Buy" by BrokeragesZymeworks (ZYME) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 5:35 AM
Zymeworks (ZYME) Receives New Coverage from Analysts at Ladenburg ThalmannZymeworks (ZYME) Receives New Coverage from Analysts at Ladenburg Thalmann
www.americanbankingnews.com - May 14 at 12:26 PM
Barclays Upgrades Zymeworks (ZYME) to Equal WeightBarclays Upgrades Zymeworks (ZYME) to Equal Weight
www.americanbankingnews.com - May 11 at 6:33 PM
Zymeworks to Present at the UBS Global Healthcare Conference 2018Zymeworks to Present at the UBS Global Healthcare Conference 2018
finance.yahoo.com - May 10 at 4:55 PM
Cormark Comments on Zymeworks Q2 2018 Earnings (ZYME)Cormark Comments on Zymeworks' Q2 2018 Earnings (ZYME)
www.americanbankingnews.com - May 4 at 5:49 AM
BRIEF-Zymeworks Files For Mixed Shelf Of Upto $250 Mln - SEC FilingBRIEF-Zymeworks Files For Mixed Shelf Of Upto $250 Mln - SEC Filing
www.reuters.com - May 3 at 9:04 AM
Zymeworks (ZYME) Stock Rating Upgraded by ValuEngineZymeworks (ZYME) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 1:15 PM
This Biotech Stock Has Surged Over 100% in 2018: Is it Still a Buy Today?This Biotech Stock Has Surged Over 100% in 2018: Is it Still a Buy Today?
www.fool.ca - May 2 at 9:09 AM
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
finance.yahoo.com - April 30 at 4:38 PM
 Brokerages Expect Zymeworks (ZYME) to Announce -$0.68 EPS Brokerages Expect Zymeworks (ZYME) to Announce -$0.68 EPS
www.americanbankingnews.com - April 28 at 5:20 AM
Zymeworks (ZYME) Expected to Post Q1 2018 Earnings of ($0.67) Per ShareZymeworks (ZYME) Expected to Post Q1 2018 Earnings of ($0.67) Per Share
www.americanbankingnews.com - April 26 at 7:54 AM
Zymeworks (ZYME) Announces Expanded Bispecific Antibody Collaboration with Celgene Corp. (CELG)Zymeworks (ZYME) Announces Expanded Bispecific Antibody Collaboration with Celgene Corp. (CELG)
www.streetinsider.com - April 25 at 9:12 AM
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual MeetingZymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 25 at 9:12 AM
BRIEF-Zymeworks And Celgene Expand Bispecific Antibody CollaborationBRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration
www.reuters.com - April 24 at 9:07 AM
Zymeworks up 15% after hours on expanded Celgene partnershipZymeworks up 15% after hours on expanded Celgene partnership
seekingalpha.com - April 23 at 4:38 PM
Zymeworks and Celgene Expand Bispecific Antibody CollaborationZymeworks and Celgene Expand Bispecific Antibody Collaboration
finance.yahoo.com - April 23 at 4:38 PM
Zymeworks (ZYME) Receives Consensus Rating of "Buy" from BrokeragesZymeworks (ZYME) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 20 at 5:25 AM
-$0.68 EPS Expected for Zymeworks Inc (ZYME) This Quarter-$0.68 EPS Expected for Zymeworks Inc (ZYME) This Quarter
www.americanbankingnews.com - April 11 at 5:17 AM
Want to Beat the TSX? Buy These 3 Stocks Poised for Monster Long-Term GrowthWant to Beat the TSX? Buy These 3 Stocks Poised for Monster Long-Term Growth
www.msn.com - April 5 at 4:39 PM
Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - April 3 at 4:43 PM
3 Drug and Nutrition Stocks That Belong in Your TFSA3 Drug and Nutrition Stocks That Belong in Your TFSA
www.fool.ca - March 26 at 4:33 PM
Zymeworks Inc (ZYME) Given Average Rating of "Buy" by BrokeragesZymeworks Inc (ZYME) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 26 at 5:41 AM
Zymeworks Inc (ZYME) Expected to Post Earnings of -$0.68 Per ShareZymeworks Inc (ZYME) Expected to Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - March 25 at 8:48 AM
Raymond James Financial Begins Coverage on Zymeworks (ZYME)Raymond James Financial Begins Coverage on Zymeworks (ZYME)
www.americanbankingnews.com - March 19 at 11:10 AM
BRIEF-Zymeworks Reports Qtrly Net Income Per Common Share $1.29BRIEF-Zymeworks Reports Qtrly Net Income Per Common Share $1.29
www.reuters.com - March 14 at 6:03 PM
Zymeworks Reports 2017 Year-End Financial ResultsZymeworks Reports 2017 Year-End Financial Results
finance.yahoo.com - March 14 at 6:03 PM
Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos AcquisitionZymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition
finance.yahoo.com - March 14 at 6:03 PM
Zymeworks to Present at Barclays 2018 Global Healthcare ConferenceZymeworks to Present at Barclays 2018 Global Healthcare Conference
finance.yahoo.com - March 7 at 5:32 PM
Zymeworks Inc (ZYME) Receives Consensus Recommendation of "Buy" from AnalystsZymeworks Inc (ZYME) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 1 at 5:30 AM
Zymeworks Opening Clinical Sites in CanadaZymeworks Opening Clinical Sites in Canada
finance.yahoo.com - February 28 at 5:14 PM
BRIEF-BDC Capital Reports 7.58 Pct Passive Stake In ZymeworksBRIEF-BDC Capital Reports 7.58 Pct Passive Stake In Zymeworks
www.reuters.com - February 14 at 4:57 PM
Critical Contrast: Zymeworks (ZYME) & The CompetitionCritical Contrast: Zymeworks (ZYME) & The Competition
www.americanbankingnews.com - February 7 at 1:12 AM
Zymeworks Inc (ZYME) Given Consensus Rating of "Hold" by BrokeragesZymeworks Inc (ZYME) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 4 at 11:14 AM
Zymeworks Inc (ZYME) Expected to Post Earnings of -$0.62 Per ShareZymeworks Inc (ZYME) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - February 2 at 8:44 AM
Contrasting Zymeworks (ZYME) and Its CompetitorsContrasting Zymeworks (ZYME) and Its Competitors
www.americanbankingnews.com - January 17 at 3:12 AM
-$0.62 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter-$0.62 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter
www.americanbankingnews.com - January 16 at 9:30 AM
Zymeworks (ZYME) Rating Lowered to Hold at Zacks Investment ResearchZymeworks (ZYME) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
Financial Survey: Verastem (VSTM) and Zymeworks (ZYME)Financial Survey: Verastem (VSTM) and Zymeworks (ZYME)
www.americanbankingnews.com - January 12 at 8:18 AM
Zymeworks Inc (ZYME) Receives Consensus Recommendation of "Hold" from AnalystsZymeworks Inc (ZYME) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 10 at 8:14 AM
Critical Analysis: Zymeworks (ZYME) and The CompetitionCritical Analysis: Zymeworks (ZYME) and The Competition
www.americanbankingnews.com - January 9 at 5:10 AM
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 PrioritiesZymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities
finance.yahoo.com - January 7 at 7:37 PM
Zymeworks Inc (ZYME) Given Average Rating of "Hold" by AnalystsZymeworks Inc (ZYME) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM
Applied BioMath, LLC to Sponsor and Present at PepTalk: The Protein Science WeekApplied BioMath, LLC to Sponsor and Present at PepTalk: The Protein Science Week
www.prnewswire.com - December 12 at 6:18 PM
Head-To-Head Survey: Affimed (AFMD) & Zymeworks (ZYME)Head-To-Head Survey: Affimed (AFMD) & Zymeworks (ZYME)
www.americanbankingnews.com - November 28 at 5:46 PM

SEC Filings

Zymeworks (NYSE:ZYME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zymeworks (NYSE:ZYME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zymeworks (NYSE ZYME) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.